Fra‑1 enhances the radioresistance of colon cancer cells to X‑ray or C‑ion radiation

Endo,Satoshi; Fujita,Mayumi; Yamada,Shigeru; Imadome,Kaori; Nakayama,Fumiaki; Isozaki,Tetsuro; Yasuda,Takeshi; Imai,Takashi; Matsubara,Hisahiro

doi:10.3892/or.2018.6223

Fra‑1 enhances the radioresistance of colon cancer cells to X‑ray or C‑ion radiation

Authors:
- Satoshi Endo
- Mayumi Fujita
- Shigeru Yamada
- Kaori Imadome
- Fumiaki Nakayama
- Tetsuro Isozaki
- Takeshi Yasuda
- Takashi Imai
- Hisahiro Matsubara
View Affiliations

Affiliations: Department of Frontier Surgery, Chiba University Graduate School of Medicine, Chiba 260‑8670, Japan, Department of Basic Medical Sciences for Radiation Damage, National Institutes for Quantum and Radiological Science and Technology, Japan, Hospital of The National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Japan, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Japan
Published online on: January 19, 2018 https://doi.org/10.3892/or.2018.6223
Pages: 1112-1118
Copyright: © Endo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fos‑related antigen 1 (Fra‑1) has roles in a variety of cell functions, including cell proliferation, differentiation, transformation, and invasiveness, and it is upregulated in various cancers. We investigated the role of Fra‑1 in cellular radioresistance using cells of two human colorectal cancer cell lines, SW620 and SW480. We found that SW620 cells are more sensitive than SW480 cells at doses greater than 6 Gy for X‑ray or 3 Gy for carbon‑ion (C‑ion) radiation. Fra‑1 expression tended to be decreased by the radiation in a dose‑dependent manner in both cell lines; of note, a greater reduction of Fra‑1 expression was observed in SW620 cells, especially at 6 Gy of X‑ray or 3 Gy of C‑ion irradiation, than in SW480 cells, indicating a possible association between Fra‑1 downregulation and cellular radiosensitivity. Knockdown of Fra‑1 in SW480 cells significantly increased the radiosensitivity to X‑ray or C‑ion radiation. On the other hand, overexpression of Fra‑1 in SW620 cells significantly enhanced the radioresistance to C‑ion radiation, suggesting a role of Fra‑1 in radioresistance. Furthermore, we found that downregulation of Fra‑1 protein in irradiated SW620 cells was regulated via protein degradation through a proteasome‑dependent pathway. Overall, our results indicate a role of Fra‑1 in radioresistance to both X‑ray and C‑ion radiation for colorectal cancer cell lines.

View Figures

View References

1	Eferl R and Wagner EF: AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer. 3:859–868. 2003. View Article : Google Scholar : PubMed/NCBI
2	Young MR and Colburn NH: Fra-1 a target for cancer prevention or intervention. Gene. 379:1–11. 2006. View Article : Google Scholar : PubMed/NCBI
3	Hu YC, Lam KY, Law S, Wong J and Srivastava G: Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: Overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin Cancer Res. 7:2213–2221. 2001.PubMed/NCBI
4	Ramos-Nino ME, Scapoli L, Martinelli M, Land S and Moss-man BT: Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res. 63:3539–3545. 2003.PubMed/NCBI
5	Hapke S, Kessler H, Luber B, Benge A, Hutzler P, Höfler H, Schmitt M and Reuning U: Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol Chem. 384:1073–1083. 2003. View Article : Google Scholar : PubMed/NCBI
6	Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E and Tulchinsky E: Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol. 18:7095–7105. 1998. View Article : Google Scholar : PubMed/NCBI
7	Diesch J, Sanij E, Gilan O, Love C, Tran H, Fleming NI, Ellul J, Amalia M, Haviv I, Pearson RB, et al: Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells. PLoS One. 9:e889502014. View Article : Google Scholar : PubMed/NCBI
8	Usui A, Hoshino I, Akutsu Y, Sakata H, Nishimori T, Murakami K, Kano M, Shuto K and Matsubara H: The molecular role of Fra-1 and its prognostic significance in human esophageal squamous cell carcinoma. Cancer. 118:3387–3396. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhang W, Hart J, McLeod HL and Wang HL: Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol. 124:11–19. 2005. View Article : Google Scholar : PubMed/NCBI
10	Zerbini LF, Wang Y, Cho JY and Libermann TA: Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res. 63:2206–2215. 2003.PubMed/NCBI
11	Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ and Hanski C: Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA. 96:pp. 1603–1608. 1999; View Article : Google Scholar : PubMed/NCBI
12	Fung LF, Lo AK, Yuen PW, Liu Y, Wang XH and Tsao SW: Differential gene expression in nasopharyngeal carcinoma cells. Life Sci. 67:923–936. 2000. View Article : Google Scholar : PubMed/NCBI
13	Belguise K, Kersual N, Galtier F and Chalbos D: FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene. 24:1434–1444. 2005. View Article : Google Scholar : PubMed/NCBI
14	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
15	Yamada S, Shinoto M, Endo S, Yasuda S, Imada H, Kamada T and Tsujii H: Carbon ion radiotherapy for patients with locally recurrent cancer. Proceedings of NIRS-IMP Joint Symposium on Carbon Ion Therapy and Radiation Emergency Med. 1–47. 2012.
16	Lingareddy V, Ahmad NR and Mohiuddin M: Palliative reirradiation for recurrent rectal cancer. Int J Radiat Oncol Biol Phys. 38:785–790. 1997. View Article : Google Scholar : PubMed/NCBI
17	Tsuji H and Kamada T: A review of update clinical results of carbon ion radiotherapy. Jpan J Clin Oncol. 42:670–685. 2012. View Article : Google Scholar
18	Fokas E, Kraft G, An H and Engenhart-Cabillic R: Ion beam radiobiology and cancer: Time to update ourselves. Biochim Biophys Acta. 1796:216–229. 2009.PubMed/NCBI
19	Schulz-Ertner D and Tsujii H: Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 25:953–964. 2007. View Article : Google Scholar : PubMed/NCBI
20	Tsuchida Y, Tsuboi K, Ohyama H, Ohno T, Nose T and Ando K: Cell death induced by high-linear-energy transfer carbon beams in human glioblastoma cell lines. Brain Tumor Pathol. 15:71–76. 1998. View Article : Google Scholar : PubMed/NCBI
21	Nakano T, Suzuki Y, Ohno T, Kato S, Suzuki M, Morita S, Sato S, Oka K and Tsujii H: Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin Cancer Res. 12:2185–2190. 2006. View Article : Google Scholar : PubMed/NCBI
22	Suzuki M, Kase Y, Yamaguchi H, Kanai T and Ando K: Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon-ion beams. Int J Radiat Oncol Biol Phys. 48:241–250. 2000. View Article : Google Scholar : PubMed/NCBI
23	Tobias CA, Blakely EA, Alpen EL, Castro JR, Ainsworth EJ, Curtis SB, Ngo FQ, Rodriguez A, Roots RJ, Tenfordf T and Yang TC: Molecular and cellular radiobiology of heavy ions. Int J Radiat Oncol Biol Phys. 8:2109–2120. 1982. View Article : Google Scholar : PubMed/NCBI
24	Allen C, Borak TB, Tsujii H and Nickoloff JA: Heavy charged particle radiobiology: Using enhanced biological effectiveness and improved beam focusing to advance cancer therapy. Mutat Res. 711:150–157. 2011. View Article : Google Scholar : PubMed/NCBI
25	Yamada S, Kamada T, Ebner DK, Shinoto M, Terashima K, Isozaki Y, Yasuda S, Makishima H, Tsuji H, Tsujii H, et al: Carbon-ion radiation therapy for pelvic recurrence of rectal cancer. Int J Radiat Oncol Biol Phys. 96:93–101. 2016. View Article : Google Scholar : PubMed/NCBI
26	Combs SE, Kieser M, Habermehl D, Weitz J, Jäger D, Fossati P, Orrechia R, Engenhart-Cabillic R, Pötter R, Dosanjh M, et al: Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: The PANDORA-01 trial. BMC Cancer. 12:1372012. View Article : Google Scholar : PubMed/NCBI
27	Matsuzaki H, Ishihara S, Kawai K, Nishikawa T, Tanaka T, Kiyomatsu T, Hata K, Nozawa H, Yamada S and Watanabe T: Late sacral recurrence of rectal cancer treated by heavy ion radiotherapy: A case report. Surg Case Rep. 2:1092016. View Article : Google Scholar : PubMed/NCBI
28	Yamada S, Shinoto M, Shigeo Y, Imada H, Kato H, Kamada T and Tsujii H: Current status and perspective of heavy ion beam therapy for patients with pelvic recurrence after primarily resected rectal cancer. Gan To Kagaku Ryoho. 36:1263–1266. 2009.(In Japanese). PubMed/NCBI
29	Mobaraki A, Ohno T, Yamada S, Sakurai H and Nakano T: Cost-effectiveness of carbon ion radiation therapy for locally recurrent rectal cancer. Cancer Sci. 101:1834–1839. 2010. View Article : Google Scholar : PubMed/NCBI
30	Habermehl D, Wagner M, Ellerbrock M, Büchler MW, Jäkel O, Debus J and Combs SE: Reirradiation using carbon ions in patients with locally recurrent rectal cancer at HIT: First results. Ann Surg Oncol. 22:2068–2074. 2015. View Article : Google Scholar : PubMed/NCBI
31	Isozaki Y, Yamada S, Kawashiro S, Yasuda S, Okada N, Ebner D, Tsuji H, Kamada T and Matsubara H: Carbon-ion radiotherapy for isolated para-aortic lymph node recurrence from colorectal cancer. J Surg Oncol. 116:932–938. 2017. View Article : Google Scholar : PubMed/NCBI
32	Peters LJ, Brock WA, Chapman JD and Wilson G: Predictive assays of tumor radiocurability. Am J Clin Oncol. 11:275–287. 1988. View Article : Google Scholar : PubMed/NCBI
33	West CM: Invited review: Intrinsic radiosensitivity as a predictor of patient response to radiotherapy. Br J Radiol. 68:827–837. 1995. View Article : Google Scholar : PubMed/NCBI
34	Ishikawa K, Koyama-Saegusa K, Otsuka Y, Ishikawa A, Kawai S, Yasuda K, Suga T, Michikawa Y, Suzuki M, Iwakawa M and Imai T: Gene expression profile changes correlating with radioresistance in human cell lines. Int J Radiat Oncol Biol Phys. 65:234–245. 2006. View Article : Google Scholar : PubMed/NCBI
35	Kajanne R, Miettinen P, Tenhunen M and Leppä S: Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells. Int J Oncol. 35:1175–1182. 2009.PubMed/NCBI
36	Fujita M, Otsuka Y, Yamada S, Iwakawa M and Imai T: X-ray irradiation and Rho-kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa-2, which exhibits mesenchymal and amoeboid motility. Cancer Sci. 102:792–798. 2011. View Article : Google Scholar : PubMed/NCBI
37	Fujita M, Imadome K, Shoji Y, Isozaki T, Endo S, Yamada S and Imai T: Carbon-ion irradiation suppresses migration and invasiveness of human pancreatic carcinoma cells MIAPaCa-2 via Rac1 and RhoA degradation. Int J Radiat Oncol Biol Phys. 93:173–180. 2015. View Article : Google Scholar : PubMed/NCBI
38	Fujita M, Otsuka Y, Imadome K, Endo S, Yamada S and Imai T: Carbon-ion radiation enhances migration ability and invasiveness of the pancreatic cancer cell, PANC-1, in vitro. Cancer Sci. 103:677–683. 2012. View Article : Google Scholar : PubMed/NCBI
39	Basbous J, Jariel-Encontre I, Gomard T, Bossis G and Piechaczyk M: Ubiquitin-independent-versus ubiquitin-dependent proteasomal degradation of the c-Fos and Fra-1 transcription factors: Is there a unique answer? Biochimie. 90:296–305. 2008. View Article : Google Scholar : PubMed/NCBI
40	Sasaki H, Yatagai F, Kanai T, Furusawa Y, Hanaoka F, Zhu WG and Mehnati P: Dependence of induction of interphase death of Chinese hamster ovary cells exposed to accelerated heavy ions on linear energy transfer. Radiat Res. 148:449–454. 1997. View Article : Google Scholar : PubMed/NCBI
41	Casalino L, Bakiri L, Talotta F, Weitzman JB, Fusco A, Yaniv M and Verde P: Fra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcription. EMBO J. 26:1878–1890. 2007. View Article : Google Scholar : PubMed/NCBI
42	Vial E and Marshall CJ: Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J Cell Sci. 116:4957–4963. 2003. View Article : Google Scholar : PubMed/NCBI
43	Casalino L, De Cesare D and Verde P: Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilization. Mol Cell Biol. 23:4401–4415. 2003. View Article : Google Scholar : PubMed/NCBI
44	Basbous J, Chalbos D, Hipskind R, Jariel-Encontre I and Piechaczyk M: Ubiquitin-independent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabilizer. Mol Cell Biol. 27:3936–3950. 2007. View Article : Google Scholar : PubMed/NCBI